Bartek Ingredients Purchases New State-of-the-Art Maleic Anhydride Reactor
3.9.2019 18:25:00 EEST | Business Wire | Press release
On the heels of its successful expansion of its malic and fumaric acid finishing capacity earlier in 2019, Bartek Ingredients announced the decision to purchase a 22,000 metric tons/year reactor from MAN Energy Solutions in Deggendorf, Germany.
The reactor will expand the company’s maleic anhydride capacity ahead of anticipated long-term growth in the global acidulants market. It further integrates Bartek’s upstream raw material production with its downstream finishing capacity.
“The new reactor will be a welcome addition to the North American market, where additional capacity is projected to be required by 2023,” Bartek CEO John Burrows said. “Bartek is committed to leading the global market in malic and food grade fumaric acid, and ensuring that our customers are supplied for years to come is a vital element of our long-term strategy.”
Bartek expects delivery of this new reactor in Q4 2020 with the capacity to be online in Q2 2021.
“This investment decision by the Bartek board supports the company’s strategy of investing ahead of market demand and reinforces the company’s objective to operate a best-in-class manufacturing operation,” said Matt Chapman, partner at Bartek’s parent company, TorQuest Partners.
For more information about Bartek and its products, visit bartek.ca.
About Bartek Ingredients
Established in 1969, Bartek Ingredients Inc. is a leading producer of malic acid, fumaric acid, and maleic anhydride. Headquartered in Stoney Creek, Ontario, Canada, Bartek employs 120 people across its two production facilities in Southern Ontario. Bartek’s facilities are registered to the ISO 9001:2015 Standard. Bartek also holds the BRC Global Standard for Food Safety certification, and it distributes to more than 40 countries around the world. For more information about Bartek, visit bartek.ca/.
About TorQuest Partners
Founded in 2002, TorQuest Partners is a Canadian-based manager of private equity funds. With more than C$2 billion of equity capital under management, TorQuest invests in middle market companies and works in close partnership with management to build value. To learn more about TorQuest Partners, visit torquest.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190903005672/en/
Contact information
Erin Robbins
MarketPlace
erin.robbins@market-pl.com
+1-314-366-3562
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The LYCRA Company Launches LYCRA ® ADAPTIV fiber for Nonwovens, Advancing Comfort and Fit in Disposable Hygiene at INDEX™ 2613.5.2026 15:00:00 EEST | Press release
The LYCRA Company, a leader in innovative and sustainable fibers for apparel and personal care, today announced the official global launch of LYCRA® ADAPTIV fiber for nonwovens at INDEX™ 26, in Geneva, Switzerland, May 19–22. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514856391/en/ At INDEX™ 26 in Geneva, The LYCRA Company debuts LYCRA® ADAPTIV fiber for nonwovens, a next-generation stretch solution that delivers enhanced comfort, a secure fit, and helps enable inclusive sizing for baby diapers, adult incontinence, and feminine care products. This breakthrough stretch fiber, already trusted by leading global apparel brands, now ushers in a new era of comfort, fit, and performance for baby diapers, disposable hygiene products, adult incontinence, and feminine care. LYCRA® ADAPTIV fiber is engineered to address key unmet needs in hygiene and personal care. According to the company’s proprietary research, these include f
Adtran expands SDG 8700 Series to deliver Wi-Fi 7 at scale13.5.2026 15:00:00 EEST | Press release
Adtran today announced an expansion of its SDG 8700 Series, extending Wi-Fi 7 across a broader range of residential service tiers and deployment models. The expanded portfolio introduces new 2.5Gbit/s and 10Gbit/s Wi-Fi 7 platforms designed to support the full spectrum of multigigabit services – from entry-level offerings to premium tiers – across residential, SMB, MDU and community Wi-Fi deployments. As service providers enter a new access refresh cycle, Wi-Fi 7 is rapidly becoming a baseline requirement rather than a premium differentiator. Adtran’s expanded SDG 8700 portfolio enables providers to deploy next-generation Wi-Fi more broadly and consistently without compromising subscriber experience or changing operational models. The launch also builds on the FCC’s recent conditional approval of Adtran’s SDG portfolio, supporting continued broadband rollout momentum. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202605130036
Austrian Broadband Operator Deploys Vecima’s Entra ® vCMTS and Remote PHY Devices to Advance its Next-Generation DOCSIS ® Network13.5.2026 14:45:00 EEST | Press release
Vecima Networks Inc. (TSX: VCM) and Witke today announced that an Austrian broadband operator is deploying the Entra® virtualized Cable Modem Termination System (vCMTS) as the DOCSIS® platform for its Distributed Access Architecture (DAA) evolution. The deployment, led by Witke, enables advanced reliability, scalable capacity expansion over time, and a clear migration path toward DOCSIS 4.0 broadband services. After extensive system planning and evaluation, the operator selected a vCMTS and Remote PHY (R-PHY) architecture to align with its long-term network roll-out strategy and migration requirements. The deployment provides the flexibility to modernize the network in phases while reducing space, power, and cooling requirements across the operator’s infrastructure. Entra vCMTS establishes a new standard for simplified, virtualized Cable Access, combining a modern microservices architecture with commercial off-the-shelf (COTS) hardware to deliver next-generation flexibility while enhan
Vecima, Incognito, and BM COM Announce Turnkey Fiber Broadband Solutions at ANGA COM 202613.5.2026 14:30:00 EEST | Press release
Vecima Networks Inc., Incognito Software Systems Inc., and BM COM s.r.o., today announced a strategic collaboration to deliver a fully integrated, turnkey fiber broadband solution, which will be showcased at ANGA COM 2026, May 19–21 in Cologne, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513492655/en/ The joint solution brings together best-in-class fiber access infrastructure, advanced service orchestration, and in-market deployment expertise into a unified, interoperable Broadband-in-a-Box platform without requiring single vendor lock-in. Designed to simplify and accelerate fiber broadband rollouts, the solution enables operators—particularly regional and emerging providers—to deploy scalable, high-performance networks with reduced complexity and faster time to revenue. The joint Vecima, Incognito, and BM COM Broadband-in-a-Box solution integrates: Vecima’s Entra® XGS-PON platform, delivering scalable, high-
Veristat Launches AI Biostatistics Platform, Cutting Clinical Trial Data Readout Time from 5 Weeks to 5 Days * Without Regulatory Risks13.5.2026 14:05:00 EEST | Press release
Veristat™, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced the launch of InStat™ by Veristat. InStat is the clinical research industry’s first zero-code, fully automated biostatistics solution, reducing manual effort to speed time to approval with every output backed by validated statistical engines and expert biostatistician review. It delivers submission-ready tables, listings, and figures (TLF) in five days or less*, rather than the four to six weeks sponsors typically wait after database lock, while maintaining the highest quality data. Veristat will begin using InStat to deliver biostatistics services in June. Clene Nanomedicine is the first clinical trial sponsor whose work was delivered using InStat, with NfL biomarker analyses supporting their planned 2026 New Drug Application (NDA). "Following recent FDA interactions, we are advancing our NDA submission for CNM-Au8 with NfL biomarker concordance evidence as a core compon
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom